Navigation Links
Surfacing for Success: Emergent Technologies and KODE Biotech Join Forces to Expand Markets for Platform Technology

Austin, Texas and Auckland, New Zealand (PRWEB) September 10, 2013

Emergent Technologies, Inc. a leading innovation solutions company and KODE Biotech, Ltd, developer of the revolutionary KODE™ biosurface modification technology, have entered into a commercialization agreement in which Emergent will be KODE Biotech’s agent for technology commercialization. The agreement provides for revenue sharing between Emergent and KODE Biotech and has the potential to generate $5 – 10M in annual licensing revenues.

Biological processes are mediated by cell-cell and cell-surface interactions. KODE™ biosurface modification technology provides “biological paints” that can be used to apply virtually any bioactive compound to virtually any surface in just minutes without the need for any specialized equipment.

“Our technology represents a platform of constructs that can be used to modify cells, viruses, gels, solutions and solids such as glass and metal,” said Steve Henry, KODE Biotech’s CEO/CSO and Professor of Biotech Innovation at the Auckland University of Technology (AUT) Biotech Innovation Centre. “We have a proven track record in the transfusion medicine industry, where our products are being used to make quality controls and specialized diagnostic screening assays in a variety of novel diagnostic and therapeutic products."

“KODE Biotech’s technological capabilities and broad platform are a perfect fit for our innovation-based, partner-driven model,” said Thomas Harlan, Emergent CEO. “Our expertise is in locating, engaging and executing licensing deals between established companies looking for innovative solutions to protect and grow their core businesses and smaller companies like KODE Biotech that have developed such technology but lack the infrastructure and resources to see it reach its full commercialization potential.”

Under the terms of the agreement, Emergent will pursue existing leads, identify new areas of application, and process new business development opportunities from its headquarters in Austin. KODE Biotech will continue with its current commercialization, but shift to focus more on R&D from its on-campus base at AUT University providing Proof-of-Concept studies for the new business development opportunities. The companies are evaluating a KODE™-branded market-facing entity to be established in the US, from which Emergent will conduct KODE™ commercialization related business.

About Emergent Technologies, Inc.

Headquartered in Austin, Texas, Emergent Technologies, Inc. (Emergent) utilizes its innovation-based, partner-driven model to identify, manage, develop and bring to market game-changing scientific discoveries. Emergent's diverse business and technical team along with its unique innovation process of transforming scientific breakthroughs into technology platforms with multiple applications, maximizes the value of promising ideas and underutilized intellectual properties without the risk associated with commercial development. Emergent applies its experience and expertise to provide investors, entrepreneurs, start-up companies and industry partners access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. Visit for more information.

About KODE Biotech, Ltd

Based on the AUT University campus in Auckland, New Zealand, KODE Biotech, Ltd is a private company established in 1996 to commercialize and license use of KODE™ biosurface modification technology. Working together with AUT University (, KODE Biotech has developed the platform for rapid modification of virtually any surface with any functional molecule without the need for special equipment or processes. KODE™ biosurface modification technology offers significant opportunities for industrial and life science innovation and product improvement. For more information, visit the KODE Biotech website at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Customer Satisfaction, A key to Success: Narang Medical Limited
2. Emergent and DiFusion Form Strategic Partnership to Take CleanFuze™ Antimicrobial Implants to Market
3. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
4. Eckert & Ziegler Vitalea Science and Korea-based BioCore Bring Human Microdosing to Korea to Address the Needs of the Emergent Pharmaceutical Industry
5. Cardiovascular Drug Delivery - Technologies, Markets and Companies - Updated 2012 Report
6. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
7. HealthCare, Technology Briefing: Market Movers for the Week - Technologies-Scan Corp, GNC, Galena Biopharma, Immunomedics, Amarin
8. Bayer CropScience and MS Technologies Receive Approval for Balance GT Soybean Technology in the United States
9. Growing Industry in Technologies For Circulating Tumor Cells: Kalorama Report
10. BioStorage Technologies Launches INTEGRITY Study to Measure Effect of Time, Temperature and Preparation Methods on DNA and RNA Samples
11. BioLife Solutions Expands Strategic Relationship with STEMCELL Technologies Inc.
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently formed ... entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. The ... gene editing across all applications. , Under the terms of the agreement, Pioneer ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first-ever genomics analysis platform specifically designed for life science researchers to analyze ... pioneering researcher Rosalind Franklin, who made a major contribution to the discovery ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):